Hemagglutinin 5 (H5) - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 50 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hemagglutinin 5 (H5) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Hemagglutinin 5 (H5) - Pipeline Review, H2 2016', provides in depth analysis on Hemagglutinin 5 (H5) targeted pipeline therapeutics. 

The report provides comprehensive information on the Hemagglutinin 5 (H5) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hemagglutinin 5 (H5) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Hemagglutinin 5 (H5) 
- The report reviews Hemagglutinin 5 (H5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Hemagglutinin 5 (H5) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Hemagglutinin 5 (H5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Hemagglutinin 5 (H5) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Hemagglutinin 5 (H5) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hemagglutinin 5 (H5) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential ands scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hemagglutinin 5 (H5) Overview 6
Therapeutics Development 7
Hemagglutinin 5 (H5) - Products under Development by Stage of Development 7
Hemagglutinin 5 (H5) - Products under Development by Therapy Area 8
Hemagglutinin 5 (H5) - Products under Development by Indication 9
Hemagglutinin 5 (H5) - Pipeline Products Glance 10
Early Stage Products 10
Hemagglutinin 5 (H5) - Products under Development by Companies 11
Hemagglutinin 5 (H5) - Therapeutics Assessment 13
Assessment by Monotherapy/Combination Products 13
Assessment by Mechanism of Action 14
Assessment by Route of Administration 15
Assessment by Molecule Type 17
Hemagglutinin 5 (H5) - Companies Involved in Therapeutics Development 19
Altravax Inc 19
Ilyang Pharmaceutical Co Ltd 20
Inovio Pharmaceuticals Inc 21
NewLink Genetics Corp 22
Vaxine Pty Ltd 23
Hemagglutinin 5 (H5) - Drug Profiles 24
DPC-005 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
influenza [strain A/H5N1] (split virion) vaccine - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
influenza [strain A/H5N1] vaccine - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
influenza [strain A/H5N1] vaccine - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
influenza vaccine 2 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
INO-3510 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
IY-7640 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
VGX-3400X - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Hemagglutinin 5 (H5) - Dormant Projects 33
Hemagglutinin 5 (H5) - Featured News & Press Releases 34
Sep 06, 2012: Inovio Pharma Takes Major Stride Toward Universal Influenza Vaccine 34
Jul 10, 2012: Inovio Pharma Initiates Phase I H1N1 Universal Influenza Vaccine Clinical Trial 35
May 16, 2012: Inovio Pharma's Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses In Phase I Trial 36
May 16, 2012: Inovio's Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses In Phase I Trial 38
Mar 26, 2012: Inovio Receives US Patent For SynCon H1N1 Influenza Universal Vaccine 39
Jan 31, 2012: Inovio Pharmaceuticals Moves Closer To Universal Influenza Vaccine By Demonstrating Protective Immune Responses Against Multiple H3N2 And Type B Strains In Animal Studies 40
Nov 17, 2011: Inovio's Synthetic Avian Flu Vaccine Demonstrates Inhibition Of Multiple H5N1 Strains In Phase I Trial 41
Jul 14, 2011: Inovio Demonstrates Positive Immune Responses In Phase I Clinical Trial of SynCon H5N1 Influenza Vaccine 43
Jul 14, 2011: Inovio Launches Multi-Subtype Influenza Vaccine Phase I Trial 44
Sep 30, 2010: About Inovio's SynCon Universal Influenza Vaccines 45
Sep 30, 2010: Inovio's SynCon Universal Influenza DNA Vaccine Technology Recognized With NIH Director's Transformative Research Award 45
Jun 15, 2010: Inovio Immunizes First Subject In US Influenza DNA Vaccine Clinical Trial 46
Mar 02, 2010: Inovio Receives Korean Approval To Begin Clinical Trials Of H5N1 Avian Influenza DNA Vaccine 47
Nov 20, 2009: Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seasonal & Pandemic Influenza Viruses In Pre-Clinical Studies 47
Nov 20, 2009: Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seasonal & Pandemic Influenza Viruses In Pre-Clinical Studies 48

Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 49
Disclaimer 50

List of Tables

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Products under Development by Companies, H2 2016 12
Assessment by Monotherapy/Combination Products, H2 2016 13
Number of Products by Stage and Mechanism of Action, H2 2016 14
Number of Products by Stage and Route of Administration, H2 2016 16
Number of Products by Stage and Molecule Type, H2 2016 18
Pipeline by Altravax Inc, H2 2016 19
Pipeline by Ilyang Pharmaceutical Co Ltd, H2 2016 20
Pipeline by Inovio Pharmaceuticals Inc, H2 2016 21
Pipeline by NewLink Genetics Corp, H2 2016 22
Pipeline by Vaxine Pty Ltd, H2 2016 23
Dormant Projects, H2 2016 33